WARRANT SERIES TO 1 – APRIL 1-15, 2025
Our Vision
Our vision is to be a leader in identifying, developing and commercializing novel drugs that address unmet needs of people with rare cancer conditions.
Learn more about Ascelia Pharma:
TOP STORIES
Ascelia Pharma Announces Positive Outcomes of FDA Meeting and Confirms Plan to Submit the NDA for Orviglance mid-2025
2025-03-18
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that the Company has received final minutes from [… …
TOP STORIES
Ascelia Pharma Announces Acceptance of Three Scientific Abstracts with SPARKLE Phase 3 Data at the European Society of Gastrointestinal and Abdominal Radiology Annual Meeting
2025-01-27 07:30:00
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that two oral presentations and one scientific poster [&he …
TOP STORIES
Quarterly Report Q3: Successful Outcome from Rights Issue with SEK 105 Million Extends Runway Until Late 2025
2024-11-07 07:30:00
Ascelia Pharma AB (publ) (ticker: ACE) today published its Interim Report Q3 for 2024 (January – September), which is now available on the company’s website: https://www.ascelia.com/ir-med …
Latest News
Presentations & Articles
INVESTOR
Shortcut to our latest Financial Reports
Key downloads
Annual Report 2024: Orviglance Advances to Registration Phase after Successful Phase 3 Study CompletionQ4 and Full Year Report 2024: Completion of Full Study Report Reinforces Successful Outcomes of SPARKLE Phase 3 StudyQuarterly Report Q3: Successful Outcome from Rights Issue with SEK 105 Million Extends Runway Until Late 2025Half-Year Report 2024: Orviglance Completes Clinical Development with Successful Phase 3 StudyQuarterly Report Q1: Primary Endpoint Met with Strong Headline Results in Orviglance Phase 3 Study